FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2120171585> ?p ?o ?g. }

• W2120171585 endingPage "1824" @default.
• W2120171585 startingPage "1815" @default.
• W2120171585 abstract "BMS-690514 is a potent, reversible oral inhibitor of epidermal growth factor receptor (EGFR/HER-1), HER-2 and -4, and vascular endothelial growth factor receptors (VEGFRs)-1 to -3 offering targeted inhibition of tumour growth and vascularisation in a single agent. This phase I-IIa study was designed to identify the maximum tolerated dose (MTD) and assess safety, antitumour activity, pharmacokinetics and pharmacodynamics of BMS-690514.In phase I, patients with advanced solid tumours received escalating doses of once-daily BMS-690514. In phase IIa, erlotinib-naïve (cohort A) or erlotinib-resistant (cohort B) patients with advanced non-small-cell lung cancer (NSCLC) received BMS-690514 once-daily at the MTD.In phase I (n=28), the MTD was determined to be 200mg daily. BMS-690514 was rapidly absorbed and highly metabolised after repeated oral administration with minimum drug accumulation. In phase IIa (n=62), the most frequent treatment-related adverse events were diarrhoea and acneiform rash. Adverse events that led to >1 discontinuation were diarrhoea (n=4; 4%) and rash (n=2; 2%). Disease control (≥4months) and objective response rates, respectively, were 43.3% and 3.3% (cohort A) and 22.6% and 3.2% (cohort B). Six of 21 (29%) NSCLC patients with wild-type EGFR achieved disease control versus seven of 10 (70%) patients with EGFR mutations (including T790M). At MTD, BMS-690514 modulated pharmacodynamic biomarkers associated with inhibition of VEGFR- and EGFR-signalling pathways.This phase I-IIa study suggests that BMS-690514 has manageable safety profile and antitumour activity in patients with NSCLC at 200mg/d, including those with EGFR mutations conferring resistance to erlotinib." @default.
• W2120171585 created "2016-06-24" @default.
• W2120171585 creator A5000470144 @default.
• W2120171585 creator A5008593691 @default.
• W2120171585 creator A5011012477 @default.
• W2120171585 creator A5012282947 @default.
• W2120171585 creator A5018361694 @default.
• W2120171585 creator A5029761367 @default.
• W2120171585 creator A5030914311 @default.
• W2120171585 creator A5041357873 @default.
• W2120171585 creator A5045620374 @default.
• W2120171585 creator A5045670207 @default.
• W2120171585 creator A5048077180 @default.
• W2120171585 creator A5059651428 @default.
• W2120171585 creator A5074428655 @default.
• W2120171585 creator A5075347427 @default.
• W2120171585 creator A5077884585 @default.
• W2120171585 creator A5089962252 @default.
• W2120171585 creator A5090084959 @default.
• W2120171585 date "2013-05-01" @default.
• W2120171585 modified "2023-10-16" @default.
• W2120171585 title "Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours" @default.
• W2120171585 cites W1664817186 @default.
• W2120171585 cites W1965024282 @default.
• W2120171585 cites W1971837077 @default.
• W2120171585 cites W1972727274 @default.
• W2120171585 cites W1974024530 @default.
• W2120171585 cites W1977368450 @default.
• W2120171585 cites W1983622721 @default.
• W2120171585 cites W1999966467 @default.
• W2120171585 cites W2034287995 @default.
• W2120171585 cites W2038827789 @default.
• W2120171585 cites W2063171301 @default.
• W2120171585 cites W2068644483 @default.
• W2120171585 cites W2070767967 @default.
• W2120171585 cites W2071274102 @default.
• W2120171585 cites W2080267208 @default.
• W2120171585 cites W2086293120 @default.
• W2120171585 cites W2094949968 @default.
• W2120171585 cites W2099545363 @default.
• W2120171585 cites W2105121109 @default.
• W2120171585 cites W2106660927 @default.
• W2120171585 cites W2110444464 @default.
• W2120171585 cites W2114211001 @default.
• W2120171585 cites W2115078104 @default.
• W2120171585 cites W2120718661 @default.
• W2120171585 cites W2122724278 @default.
• W2120171585 cites W2126275851 @default.
• W2120171585 cites W2138297714 @default.
• W2120171585 cites W2142564546 @default.
• W2120171585 cites W2144660856 @default.
• W2120171585 cites W2145835533 @default.
• W2120171585 cites W2149456801 @default.
• W2120171585 cites W2155338842 @default.
• W2120171585 cites W2157769714 @default.
• W2120171585 cites W2160866033 @default.
• W2120171585 cites W2161557170 @default.
• W2120171585 cites W2164802689 @default.
• W2120171585 cites W2318605753 @default.
• W2120171585 doi "https://doi.org/10.1016/j.ejca.2013.02.012" @default.
• W2120171585 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23490650" @default.
• W2120171585 hasPublicationYear "2013" @default.
• W2120171585 type Work @default.
• W2120171585 sameAs 2120171585 @default.
• W2120171585 citedByCount "17" @default.
• W2120171585 countsByYear W21201715852013 @default.
• W2120171585 countsByYear W21201715852014 @default.
• W2120171585 countsByYear W21201715852015 @default.
• W2120171585 countsByYear W21201715852017 @default.
• W2120171585 countsByYear W21201715852018 @default.
• W2120171585 countsByYear W21201715852019 @default.
• W2120171585 countsByYear W21201715852021 @default.
• W2120171585 crossrefType "journal-article" @default.
• W2120171585 hasAuthorship W2120171585A5000470144 @default.
• W2120171585 hasAuthorship W2120171585A5008593691 @default.
• W2120171585 hasAuthorship W2120171585A5011012477 @default.
• W2120171585 hasAuthorship W2120171585A5012282947 @default.
• W2120171585 hasAuthorship W2120171585A5018361694 @default.
• W2120171585 hasAuthorship W2120171585A5029761367 @default.
• W2120171585 hasAuthorship W2120171585A5030914311 @default.
• W2120171585 hasAuthorship W2120171585A5041357873 @default.
• W2120171585 hasAuthorship W2120171585A5045620374 @default.
• W2120171585 hasAuthorship W2120171585A5045670207 @default.
• W2120171585 hasAuthorship W2120171585A5048077180 @default.
• W2120171585 hasAuthorship W2120171585A5059651428 @default.
• W2120171585 hasAuthorship W2120171585A5074428655 @default.
• W2120171585 hasAuthorship W2120171585A5075347427 @default.
• W2120171585 hasAuthorship W2120171585A5077884585 @default.
• W2120171585 hasAuthorship W2120171585A5089962252 @default.
• W2120171585 hasAuthorship W2120171585A5090084959 @default.
• W2120171585 hasConcept C111113717 @default.
• W2120171585 hasConcept C112705442 @default.
• W2120171585 hasConcept C121608353 @default.
• W2120171585 hasConcept C126322002 @default.
• W2120171585 hasConcept C143998085 @default.
• W2120171585 hasConcept C197934379 @default.
• W2120171585 hasConcept C2777930144 @default.
• W2120171585 hasConcept C2778087573 @default.

• next